Nirsevimab

Nirsevimab is an investigational monoclonal antibody (mAb) being developed by Merck Sharp & Dohme Corp. and Pfizer, Inc. as a potential treatment for COVID-19. The antibody targets the Spike protein of the SARS-CoV-2 virus, which helps the virus attach and invade host cells. Nirsevimab is being studied in a Phase 1/2 clinical trial to evaluate its safety and efficacy in treating mild to moderate cases of COVID-19 in adults. The trial is expected to be completed in late 2021.

Nirsevimab, sold under the brand name Beyfortus, is a human-made protein belonging to a class of medications called monoclonal antibodies. Here's a breakdown of its key characteristics:

• Function: Designed to prevent lower respiratory tract infections caused by the Respiratory Syncytial Virus (RSV) in infants and young children.
• Mechanism: Nirsevimab binds to a specific protein (F protein) on the surface of the RSV virus, preventing it from entering and infecting the cells in the respiratory tract.
• Target age group:
  • Approved by the US FDA in July 2023 for:
    • Infants born during or entering their first RSV season
    • Children up to 24 months old who are vulnerable to severe RSV disease in their second season
  • In the European Union: indicated for the prevention of RSV in neonates and infants during their first RSV season.

Key points to remember:

• Nirsevimab is administered as a single dose injection.
• It provides passive immunity, meaning it offers temporary protection without stimulating the body's own immune response like a traditional vaccine.
• Studies show Nirsevimab can reduce the risk of severe RSV disease by about 80% and offers protection for at least 5 months, covering the typical RSV season.
• Nirsevimab is not a substitute for routine childhood vaccinations.
• It's crucial to consult a healthcare professional to determine if Nirsevimab is suitable for a specific child, considering their individual health status and risk factors.
•